Innoviva (INVA) Price & Analysis

Compare

313 Followers

INVA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$16.67 - $22.00

Previous CloseN/A

Volume64.08K

Average Volume (3M)797.29K

Market Cap

$1.26B

Enterprise Value$1.72B

Total Cash (Recent Filing)$497.73M

Total Debt (Recent Filing)$450.90M

Price to Earnings (P/E)59.8

Beta0.34

Next Earnings

Oct 29, 2025

EPS Estimate

0.48

Last Dividend Ex-Date

Sep 08, 2015

Dividend YieldN/A

Share Statistics

EPS (TTM)0.77

Shares Outstanding63,021,015

10 Day Avg. Volume743,564

30 Day Avg. Volume797,294

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.37

Enterprise Value/Revenue4.64

Enterprise Value/Gross Profit5.25

Enterprise Value/Ebitda15.39

Forecast

1Y Price Target

$40.25

Price Target Upside102.87% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

EarningsThe company reported net earnings of $0.77 per diluted share, handily beating the forecast for net earnings of only $0.57 per diluted share.

Financial PerformanceInnoviva's financial results demonstrate strong underlying operational performance, with multiple revenue streams exceeding expectations.

Product DevelopmentAn 85% probability of approval is assigned to zoliflodacin based on favorable clinical data, drawing attention to a potential near-term regulatory decision.

Bears Say

ValuationInnoviva's current valuation may not adequately account for the net present value of the respiratory product royalties that the firm may receive.

Innoviva News

Arm initiated, Adobe downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

18d ago

ARM

Innoviva initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Innoviva (INVA) with an Outperform rating and $35 price target Innoviva is a holding...

18d ago

INVA

Innoviva price target raised to $45 from $40 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Innoviva (INVA) to $45 from $40 and...

18d ago

INVA

Innoviva reports Q2 EPS 77c vs. (55c) last year

Reports Q2 revenue $100.3M vs. $99.9M last year. “Innoviva (INVA) continued to deliver impressive financial and operational results...

22d ago

INVA

Innoviva Reports Strong Q2 2025 Financial Results

Innoviva ( ($INVA) ) has released its Q2 earnings. Here is a breakdown of the information Innoviva presented...

22d ago

INVA

INVA Upcoming Earnings Report: What to Expect?

Innoviva (INVA) is scheduled to report 2nd quarter earnings on 07/30/2025. Regarding Q2 estimates, Wall Street analysts expect...

1M ago

INVA

Innoviva initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Innoviva (INVA) with a Buy rating and $40 price target The firm says...

2M ago

INVA

Innoviva initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Innoviva (INVA) with an Overweight rating and $26 price target Published first on...

2M ago

INVA

Innoviva announces zoliflodacin NDA granted Priority Review by FDA

Innoviva (INVA) announced that the FDA has granted Priority Review for the New Drug Application for zoliflodacin, an...

3M ago

INVA

Innoviva Specialty Therapeutics announces FDA accepts NDA for zoliflodacin

Innoviva (INVA) Specialty Therapeutics, a subsidiary of Innoviva, in collaboration with the Global Antibiotic Research & Development Partnership,...

3M ago

INVA

Innoviva Elects Board Members and Approves Compensation

Innoviva ( ($INVA) ) just unveiled an update. At the Annual Meeting of Stockholders on May 19, 2025,...

3M ago

INVA

Innoviva subsidiary announces U.S. commercial availability of ZEVTERA

Innoviva (INVA) Specialty Therapeutics, a subsidiary of Innoviva, announced the United States commercial availability of ZEVTERA, the newest...

3M ago

INVA

Innoviva’s Strong Q1 2025 Performance and Strategic Progress

Innoviva ( ($INVA) ) has released its Q1 earnings. Here is a breakdown of the information Innoviva presented...

4M ago

INVA

Innoviva reports Q1 EPS (74c) vs. 46c last year

Reports Q1 revenue $88.6M vs. $77.50M last year. The company said, “We are pleased with our strong first...

4M ago

INVA

INVA FAQ

What was Innoviva’s price range in the past 12 months?

Innoviva lowest stock price was $16.67 and its highest was $22.00 in the past 12 months.

What is Innoviva’s market cap?

Innoviva’s market cap is $1.26B.

When is Innoviva’s upcoming earnings report date?

Innoviva’s upcoming earnings report date is Oct 29, 2025 which is in 61 days.

How were Innoviva’s earnings last quarter?

Innoviva released its earnings results on Aug 06, 2025. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.499 by $0.271.

Is Innoviva overvalued?

According to Wall Street analysts Innoviva’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Innoviva pay dividends?

Innoviva pays a Quarterly dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva dividends here

What is Innoviva’s EPS estimate?

Innoviva’s EPS estimate is 0.48.

How many shares outstanding does Innoviva have?

Innoviva has 63,021,015 shares outstanding.

What happened to Innoviva’s price movement after its last earnings report?

Innoviva reported an EPS of $0.77 in its last earnings report, beating expectations of $0.499. Following the earnings report the stock price went up 1.151%.

Which hedge fund is a major shareholder of Innoviva?

Currently, no hedge funds are holding shares in INVA

Innoviva Stock Smart Score

Outperform

Fundamentals

Return on Equity

5.60%

Trailing 12-Months

Asset Growth

8.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Innoviva

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Innoviva (INVA) Earnings & Revenues

Historic Earnings Reports

INVA Stock 12 Month Forecast

Average Price Target

$40.25

▲(102.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","33":"$33","56":"$56","21.5":"$21.5","44.5":"$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,21.5,33,44.5,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.63,21.427692307692308,24.225384615384616,27.02307692307692,29.82076923076923,32.61846153846154,35.41615384615385,38.213846153846156,41.011538461538464,43.80923076923077,46.60692307692308,49.40461538461539,52.2023076923077,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.63,20.29307692307692,21.956153846153846,23.619230769230768,25.28230769230769,26.945384615384615,28.608461538461537,30.271538461538462,31.934615384615384,33.597692307692306,35.26076923076923,36.923846153846156,38.58692307692307,{"y":40.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.63,19.196923076923078,19.763846153846153,20.33076923076923,20.897692307692306,21.464615384615385,22.03153846153846,22.59846153846154,23.165384615384614,23.732307692307693,24.299230769230768,24.866153846153846,25.433076923076925,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.69,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.24,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.12,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.35,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.64,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >